LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the second quarter ended June 30, 2022 on Monday,
Top-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1 around the end of 2022 LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today
LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), today announces it will host an in-person KOL event for analysts and investors on Thursday, June 16, 2022, at 8:00 AM ET, in New York. Verona Pharma’s KOL event will feature presentations
© Verona Pharma plc 2022. All rights reserved